Navigation Links
Ocular Therapeutix, Inc. Appoints Two New Board Members
Date:10/1/2009

WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and Mr. Bernard Haffey.

Mr. Myers is currently the President, CEO and co-founder of Alimera Sciences, Inc., a biopharmaceutical company that is developing and commercializing prescription ophthalmic pharmaceuticals. Under his leadership, Alimera has raised venture funding totaling approximately $90M. Myers has over 25 years of experience in the ophthalmic pharmaceutical industry in sales, marketing, and general management. "I am pleased to have the opportunity to contribute to the Ocular Therapeutix Board of Directors. The I-ZIP® Ocular Bandage has the potential to be of great benefit to patients in the future," said Myers.

Mr. Haffey was most recently President and CEO of NDO Surgical, a medical technology company dedicated to the development of innovative endoscopic technologies for gastrointestinal diseases. Prior to this position, he joined IntraLase Corp. as Vice President, Business Development. With over 10 years experience in medical technology, Haffey has a proven track record of successfully launching emerging medical technology and medical device companies. Additionally, he has successfully helped three of his former companies through acquisition including NDO Surgical and Intralase. "I am delighted to be joining the world-class team at Ocular Therapeutix and look forward to helping the company achieve world-class business results," said Haffey.

"We are extremely fortunate to add industry veterans such as Bernie and Dan to our board. While Bernie brings commercial leadership and expertise particularly in the refractive and corneal areas, Dan has deep expertise in ophthalmic pharmaceutical and drug delivery. Their addition to our team will be key as we move forward towards commercialization of the I-ZIP bandage in the US and as we build our drug delivery programs," said Amar Sawhney, President and CEO of Ocular Therapeutix. The appointment of Mr. Haffey and Mr. Myers increases the number of Ocular Therapeutix directors to seven. Board members also include Amar Sawhney, Fred Khosravi of Access Closure, Inc., Charles Warden of Versant Ventures, Sam Wu of SV Life Sciences, and Alan Crane of Polaris Ventures.

About Ocular Therapeutix, Inc:

Ocular Therapeutix, Inc. is a privately held company based in Waltham, MA focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. The company was founded in November 2006. The I-ZIP Adherent Ocular Bandage is CE Mark approved and the I-ZIP Ocular Bandage is under clinical investigation in the United States.

I-ZIP is a registered trademark of Ocular Therapeutix, Inc.

http://www.ocutx.com

SOURCE Ocular Therapeutix, Inc.


'/>"/>
SOURCE Ocular Therapeutix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
2. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
5. VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development
6. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
9. NovaRx Appoints Industry Veteran as President and COO
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
Breaking Medicine News(10 mins):